Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism

Stem Cells. 2016 Mar;34(3):551-64. doi: 10.1002/stem.2279. Epub 2016 Feb 2.

Abstract

Ovarian cancer shows high mortality due to development of resistance to chemotherapy and relapse. Cancer stem cells (CSCs) have been suggested to be a major contributor in developing drug resistance and relapse in ovarian cancer. In this study, we isolated CSCs through sphere culture of A2780, SKOV3, OVCAR3 epithelial ovarian cancer cells and primary ovarian cancer cells from patients. We identified heat-stable factors secreted from ovarian CSCs stimulated migration and proliferation of CSCs. Mass spectrometry and ELISA analysis revealed that lysophosphatidic acid (LPA) was significantly elevated in CSC culture media compared with non-CSC culture media. Treatment of CSCs with LPA resulted in augmented CSC characteristics such as sphere-forming ability, resistance to anticancer drugs, tumorigenic potential in xenograft transplantation, and high expression of CSC-associated genes, including OCT4, SOX2, and aldehyde dehydrogenase 1. Treatment of CSCs with LPA receptor 1-specific inhibitors or silencing of LPA receptor 1 expression abrogated the LPA-stimulated CSC properties. Autotaxin, an LPA-producing enzyme, is highly secreted from ovarian CSCs, and pharmacological inhibition or knockdown of autotaxin markedly attenuated the LPA-producing, tumorigenic, and drug resistance potentials of CSCs. Clinicopathological analysis showed a significant survival disadvantage of patients with positive staining of autotaxin. In addition, we further identified that AKT1 activity was upregulated in ovarian CSCs through an LPA-dependent mechanism and silencing of AKT1 expression led to suppression of CSC characteristics. These results suggest that autotaxin-LPA-LPA receptor 1-AKT1 signaling axis is critical for maintaining CSC characteristics through an autocrine loop and provide a novel therapeutic target for ovarian CSCs.

Keywords: Aldehyde dehydrogenase; Autotaxin; Cancer stem cells; Epithelial ovarian cancer; Lysophosphatidic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ataxin-1 / genetics
  • Autocrine Communication / drug effects
  • Carcinoma, Ovarian Epithelial
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Culture Media, Conditioned
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Lysophospholipids / administration & dosage*
  • Neoplasms, Glandular and Epithelial / drug therapy*
  • Neoplasms, Glandular and Epithelial / genetics
  • Neoplasms, Glandular and Epithelial / pathology
  • Neoplastic Stem Cells / drug effects*
  • Neoplastic Stem Cells / pathology
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • Ovarian Neoplasms / pathology
  • Phosphoric Diester Hydrolases / genetics*
  • Proto-Oncogene Proteins c-akt / genetics
  • Receptors, Lysophosphatidic Acid / genetics*
  • Signal Transduction / drug effects

Substances

  • ATXN1 protein, human
  • Ataxin-1
  • Culture Media, Conditioned
  • LPAR1 protein, human
  • Lysophospholipids
  • Receptors, Lysophosphatidic Acid
  • AKT1 protein, human
  • Proto-Oncogene Proteins c-akt
  • Phosphoric Diester Hydrolases
  • alkylglycerophosphoethanolamine phosphodiesterase
  • lysophosphatidic acid